Business
RxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026
WASHINGTON, April 08, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced, in advance of the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, that over 300,000 Light Adjustable Lens® (LAL®) implants have been performed since launch, marking a significant milestone in the company’s pursuit to make customized vision correction widely available to patients. The RxSight® Light Adjustable Lens system is the first and only intraocular lens (IOL) techno
About this update from Rxsight, Inc.
[{"type":"image","alt":"RxSight, Inc.","displaySize":"","headline":null,"caption":"RxSight, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":92,"url":"https://media.zenfs.com/en/globenewswire.com/b21b6ecb1a46af6790a9c276a59298b4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lGQfqXn_sTr0kkp3EBo5ow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyOQ--/https://media.zenfs.com/en/globenewswire.com/b21b6ecb1a46af6790a9c276a59298b4","width":300,"height":92}},"lazy":false},{"type":"text","content":"WASHINGTON, April 08, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced, in advance of the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, that over 300,000 Light Adjustable Lens® (LAL®) implants have been performed since launch, marking a significant milestone in the company’s pursuit to make customized vision correction widely available to patients.","length":406,"tagName":"p"},{"type":"text","content":"The RxSight® Light Adjustable Lens system is the first and only intraocular lens (IOL) technology that enables doctors to optimize a patient’s vision after cataract surgery based on real-world visual feedback.","length":209,"tagName":"p"},{"type":"text","content":"“The 300,000 milestone is a testament to the skill and dedication of the doctors who have leveraged LAL technology to deliver best-in-class clinical outcomes for patients and strong financial performance for their practices,” said Ron Kurtz, MD, President and Chief Executive Officer of RxSight. “Of note, the rapidly expanding body of clinical evidence supporting adjustable intraocular lens technology will also be featured at the ASCRS 2026 meeting in 35 scientific presentations.”","length":484,"tagName":"p"},{"type":"text","content":"The 15 papers, 19 posters and 1 session included in these LAL presentations span a wide range of topics, from refractive accuracy to complex cases and evolving treatment strategies, highlighting both the versatility and impact of adjustability. Highlights include a presentation by Dr. Szabo (Newsome Eye, Tampa, FL), who reported binocular LAL outcomes in which 93.1% of patients achieved simultaneous 20/20 or better distance and J1 or better near, as well as a meta-analysis by Dr. Rabinovitch (Herzig Eye Institute, Ottawa, CA), demonstrating pooled accuracy with the LAL was 91.2% with...